Q4 2024 Management View CEO Daniel Scavilla highlighted record revenue of $2.519 billion for 2024, driven by $951 million in growth and a 61% increase versus the prior year. Non-GAAP EPS for the year ...
Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...
Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...
Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...
Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the ...
BTIG analyst Ryan Zimmerman raised the firm’s price target on Globus Medical (GMED) to $94 from $91 and keeps a Buy rating on the shares after ...
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth.
Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback